Gout is a form of inflammatory arthritis caused by deposition of monosodium urate crystals in and around joints when uric acid levels remain sufficiently elevated for crystal formation. These crystals activate innate immune mechanisms and trigger intense inflammation, producing characteristic episodes of sudden, severe pain, swelling, warmth and redness. The first metatarsophalangeal joint of the big toe is a classic site, but ankles, knees, feet, wrists, fingers and elbows can also be affected. An acute attack may develop rapidly, sometimes overnight, and untreated attacks commonly last around one to two weeks. Gout is therefore not simply “high uric acid”; the defining pathological event is crystal deposition and the inflammatory response to those crystals.
Uric acid is the end product of purine metabolism in humans and circulates mainly as urate at physiological pH. Hyperuricaemia can result from excessive production, reduced renal excretion or a combination of factors. The kidneys are particularly important because they regulate much of the body's urate elimination. Genetic variation in urate transporters can influence susceptibility, while chronic kidney disease and some medications can reduce urate excretion.
Diet can contribute to urate production, particularly diets high in certain purine-rich foods, and alcohol can increase risk through several metabolic mechanisms. However, many people with hyperuricaemia never develop Gout, demonstrating that elevated serum urate is a major risk factor but not synonymous with clinical gout.
Acute Gout is driven by the immune response to urate crystals. Crystals are recognised by innate immune pathways, particularly the NLRP3 inflammasome, leading to activation of inflammatory cytokines including interleukin-1 beta. Neutrophils and other immune cells accumulate in the affected joint, producing the intense inflammatory response responsible for pain, swelling and warmth. The inflammation can resolve as crystals become coated, cleared or otherwise less biologically active, but persistent hyperuricaemia allows additional crystals to accumulate. Recurrent attacks can eventually produce chronic inflammatory arthritis and deposits known as tophi, which can damage joints and surrounding tissues.
Diagnosis of Gout can sometimes be strongly suspected from the clinical pattern, but definitive identification of monosodium urate crystals is particularly valuable when the diagnosis is uncertain. Synovial fluid obtained from an affected joint can be examined under polarised light microscopy, where needle-shaped, negatively birefringent crystals are characteristic. Serum urate measurement is useful but can be misleading during an acute attack because the concentration may temporarily fall and a normal result does not exclude Gout. Ultrasound and dual-energy CT can sometimes demonstrate urate deposition when aspiration is unavailable or unsuitable. Septic arthritis must be considered urgently when a joint is acutely hot and swollen, particularly with fever or systemic illness.
Treatment of an acute Gout attack aims to suppress inflammation quickly. NSAIDs, colchicine or corticosteroids can be used depending on individual circumstances, contraindications and interactions. Long-term management has a different purpose: urate-lowering therapy reduces serum urate sufficiently to dissolve existing crystals and prevent future deposition. Medicines such as allopurinol or febuxostat can reduce urate production, while other agents have specific indications depending on renal function and treatment context. Urate-lowering therapy generally needs to be continued consistently even when symptoms disappear because the underlying crystal burden can otherwise persist. Treatment is usually adjusted to achieve an appropriate serum urate target and continued long enough for deposits to resolve.
Lifestyle factors can modify Gout risk and attack frequency, but they do not fully explain the disease. Weight reduction when appropriate, good hydration, moderation of alcohol, avoidance of crash diets and management of hypertension, diabetes, kidney disease and abnormal lipids can be useful. Certain medications, including some diuretics, can raise urate levels.
Dietary advice should not be reduced to a simplistic list of forbidden foods because overall metabolic health and sustained urate-lowering therapy are usually more important than attempting to control severe disease through diet alone. Dehydration, acute illness, injury, surgery and abrupt metabolic changes can precipitate attacks in susceptible individuals. NHS guidance also identifies alcohol, dehydration, illness and certain medicines among recognised triggers.
Gout differs from Osteoarthritis, Rheumatoid Arthritis and Psoriatic Arthritis by its crystal-driven mechanism. Osteoarthritis usually causes activity-related mechanical pain and chronic structural joint change; Rheumatoid Arthritis causes autoimmune inflammatory synovitis; Psoriatic Arthritis produces immune-mediated inflammation associated with psoriasis; Gout produces inflammation triggered by urate crystals. Gout can, however, coexist with Osteoarthritis and can eventually cause permanent joint damage if untreated. Chronic Gout may produce tophi, recurrent inflammation and kidney stones. The condition is also strongly associated with metabolic and renal disease, so identifying Gout can prompt assessment of broader cardiovascular and metabolic risk.
The historical importance of Gout comes partly from the fact that it was one of the earliest diseases in which a specific crystalline cause of inflammation was demonstrated. Modern crystallography, biochemistry and immunology have clarified how urate deposition produces inflammation and why sustained urate reduction can alter the disease's long-term course.
A common misconception is that Gout is solely a consequence of eating rich food or drinking alcohol; genetic susceptibility, renal urate handling, age, sex, medications and metabolic health all influence risk. Another misconception is that treatment is necessary only during attacks. Acute treatment controls inflammation, whereas long-term urate lowering addresses the underlying crystal burden and can prevent recurrent attacks and structural damage.
